Anti-IL17A in Axial Spondyloarthritis-Where Are We At?
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis. Clinical studies and current issues surrounding the use of secukinumab will be discussed.
Division of Rheumatology, National University Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University, Singapore, Singapore.
Peter P
PP
Cheung
IL17A; ankylosing spondylitis; biologics; spondyloarthritis; treatment outcome